# US 2024/0002866 A1 · Gadusol derivative production in bacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002866 A1
- Document ID: US20240002866A1
- Status: Published application
- Kind: A1
- Application number: 18/354,262
- Filed: 2023-07-18
- Published: 2024-01-04
- Earliest claimed: 2019-09-06
- Assignees: Oregon State University
- Applicants: Oregon State University
- Inventors: Taifo Mahmud; Andrew Robert Osborn
- Web page: https://patentgrep.com/patent/US20240002866A1

## CPC

- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 8/40: containing nitrogen (quinones containing nitrogen A61K8/355)
- A61Q 17/04: Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
- C12N 15/76: for Actinomyces; for Streptomyces
- A61K 2800/59: Mixtures
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Disclosed is a synthetic gene cluster for producing gadusol derivatives, expression vectors and host cells containing the same, methods of producing gadusol derivatives, and compositions thereof. In an example, the synthetic gene cluster includes a valA nucleotide sequence capable of expressing ValA protein; a nucleotide sequence capable of expressing methyltransferase/oxidoreductase (MT-Ox) protein; a mysC nucleotide sequence capable of expressing a MysC protein; and a mysD nucleotide sequence capable of expressing a MysD protein. In this way, gadusol derivatives can be produced in amounts sufficient for use in a variety of applications.

## Claims

### Claim 1

A synthetic gene cluster, comprising:
a valA nucleotide sequence capable of expressing ValA;
a nucleotide sequence capable of expressing methyltransferase/oxidoreductase (MT-Ox) protein;
a mysC nucleotide sequence capable of expressing a MysC protein; and
a mysD nucleotide sequence capable of expressing a MysD protein.

### Claim 2 (depends on 1)

The synthetic gene cluster of claim 1, wherein the valA nucleotide sequence is from Streptomyces hygroscopicus.

### Claim 3 (depends on 2)

The synthetic gene cluster of claim 2, wherein the valA nucleotide sequence encodes a protein that is at least 95% identical to SEQ ID NO: 6.

### Claim 4 (depends on 2)

The synthetic gene cluster of claim 2, wherein the valA nucleotide sequence is at least 95% identical to SEQ ID NO: 2.

### Claim 5 (depends on 1)

The synthetic gene cluster of claim 1, wherein the nucleotide sequence capable of expressing methyltransferase/oxidoreductase (MT-Ox) protein is a drMT-Ox nucleotide sequence from Danio rerio.

### Claim 6 (depends on 5)

The synthetic gene cluster of claim 5, wherein the drMT-Ox nucleotide sequence encodes a protein that is at least 95% identical to SEQ ID NO: 7.

### Claim 7 (depends on 5)

The synthetic gene cluster of claim 5, wherein the drMT-Ox nucleotide sequence is at least 95% identical to SEQ ID NO: 3.

### Claim 8 (depends on 1)

The synthetic gene cluster of claim 1, wherein the mysC nucleotide sequence is from Rhodococcus fascians D188.

### Claim 9 (depends on 8)

The synthetic gene cluster of claim 8, wherein the mysC nucleotide sequence encodes a protein that is at least 95% identical to SEQ ID NO: 8.

### Claim 10 (depends on 8)

The synthetic gene cluster of claim 8, wherein the mysC nucleotide sequence is at least 95% identical to SEQ ID NO: 4.

### Claim 11 (depends on 1)

The synthetic gene cluster of claim 1, wherein the mysD nucleotide sequence is from Rhodococcus fascians D188.

### Claim 12 (depends on 11)

The synthetic gene cluster of claim 11, wherein the mysD nucleotide sequence encodes a protein that is at least 95% identical to SEQ ID NO: 9.

### Claim 13 (depends on 11)

The synthetic gene cluster of claim 11, wherein the mysD nucleotide sequence is a least 95% identical to SEQ ID NO: 5.

### Claim 14

A bacterium with an expression vector with a synthetic gene cluster comprising:
a valA nucleotide sequence capable of expressing ValA;
a nucleotide sequence capable of expressing methyltransferase/oxidoreductase (MT-Ox) protein;
a mysC nucleotide sequence capable of expressing a MysC protein; and
a mysD nucleotide sequence capable of expressing a MysD protein.

### Claim 15 (depends on 14)

The bacterium of claim 14, having the accession number PTA-126147.

### Claim 16 (depends on 14)

The bacterium of claim 14, wherein the valA nucleotide sequence is at least 95% identical to SEQ ID NO: 2, the drMT-Ox nucleotide sequence is at least 95% identical to SEQ ID NO: 3, the mysC nucleotide sequence is at least 95% identical to SEQ ID NO: 4; and
the mysD nucleotide sequence is a least 95% identical to SEQ ID NO: 5.

### Claim 17

A method of producing one or more gadusol derivatives, comprising,
culturing a host cell having an expression vector with a synthetic gene cluster comprising:
a valA nucleotide sequence capable of expressing ValA;
a nucleotide sequence capable of expressing methyltransferase/oxidoreductase (MT-Ox) protein;
a mysC nucleotide sequence capable of expressing a MysC protein, and a mysD nucleotide sequence capable of expressing a MysD protein; and
isolating one or more gadusol derivatives from the culture.

### Claim 18 (depends on 17)

The method of claim 17, wherein the host cell is a S. coelicolor cell.

### Claim 19 (depends on 17)

The method of claim 17, wherein the valA nucleotide sequence is at least 95% identical to SEQ ID NO: 2, the drMT-Ox nucleotide sequence is at least 95% identical to SEQ ID NO: 3, the mysC nucleotide sequence is at least 95% identical to SEQ ID NO: 4; and
the mysD nucleotide sequence is a least 95% identical to SEQ ID NO: 5.
